Evaluation of Miricorilant on Liver Fat in Patients With MASLD (NCT06947304) | Clinical Trial Compass
Active — Not RecruitingPhase 1
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
United States9 participantsStarted 2025-08-22
Plain-language summary
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. NAFLD Activity Score (NAS) ≥ 4 (with at least 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH Clinical Research Network (CRN) fibrosis score of F0 OR
. NAS ≥ 3 (with at least 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH CRN fibrosis score of F1 OR
. NAS ≥ 2 (with at least 1 point in subcomponent of ballooning or inflammation) and a NASH CRN fibrosis score of F2-3
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is in Phase 1 and is measuring changes in liver fat production after just 6 weeks — does that mean it's still mainly focused on whether the drug is safe, rather than proving it actually improves my liver disease long-term?
2Since this trial is listed as 'active not recruiting,' is there any chance my doctor could still get me access to miricorilant through a compassionate use or expanded access program, or is that unlikely at this stage?
3The trial is measuring something called 'fasting hepatic lipogenesis' — can you explain in plain terms what that is, why it matters for my condition, and whether a 6-week change in that measurement would translate into a meaningful benefit for me?
4Given that this is a Phase 1 study with a short 6-week treatment window, would it make more sense for me to first try established treatments or lifestyle interventions for my MASLD before considering an early-phase experimental drug?
5Because MASLD and NASH can overlap with other metabolic conditions I may have, are there any specific health factors in my history that would make the risks of an early-phase drug like miricorilant higher or lower for me compared to the general study population?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in fasting hepatic lipogenesis after 6 weeks of treatment
Timeframe: Baseline to Week 6
2
Change in peak lipogenesis after 6 weeks of treatment.